Auxilium Pharmaceuticals (NASDAQ: AUXL) is
a specialty biopharmaceutical company with a focus on developing products for urologists, endocrinologists, orthopedists and select primary care physicians. The firm markets Testim, a topical testosterone gel for the treatment of hypogonadism. It also has projects in clinical development for the treatment of Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome and overactive bladder.
The stock is up 48% over the past fifteen weeks, sparked by such issues as better than expected Q3 results, upside
guidance and subsequent affirmation of FY07 revenues, and positive clinic trial developments. The news has the stock cycling through a positive trading channel. The price is consolidating at the base of that channel, where oversold CCI, MACD and Stochastic technical parameters suggest the potential for a rise back toward the top. Correspondence of the stock's 30-day moving average to the base of the channel backs the rebound notion.
Advanced Micro Devices rallies after settling Intel tiff
United Technologies fires up a deal with GE
Cramer on BloggingStocks: Not much time left for downside 
